h a t t e n b e r g / B. Bär/ F. P r e i j e r s / A. G e u r t s v a n K e s s e l , Summary. One hundred and eighty-one consecutive patients with standard-risk leukaemia were transplanted with HLAidentical sibling grafts depleted of lymphocytes using counter flow centrifugation. In 116 patients, standard conditioning was intensified by the addition of anthracyclines. Multivariate analysis revealed significantly more acute GVHD ^ grade 2 and a trend towards more chronic GVHD in patients conditioned with the addition of anthracyclines. For all patients the risk for chronic GVHD, but not for acute GVHD, increased with a higher number of T cells in the graft. The projected 5-year probability of relapse was significantly lower in the group of patients conditioned with anthracy clines; 26% versus 52% (P = 0*015). In multivariate analysis the addition of anthracyclines to the conditioning regimen was the only significant factor contributing to a lower probability of relapse. The projected 5-year probability of leukaemia-free survival [LFS] in the patients conditioned with and without the addition of anthracyclines was 56% and 36%, respectively (P = 0-004). In multivariate analysis the addition of anthracyclines to the conditioning regimen correlated significantly with a lower number of mixed chimaeras in patients at 6 and 12 months after BMT. Mixed chimaerism at 6 months after transplantation did not significantly correlate with a higher incidence of relapse in further follow-up. In contrast, mixed chimaerism at 12 months after BMT was significantly associated with higher relapse rate.
about 45% of recipients of HLA-identical marrow grafts and contributes to death in 20-70% of those affected Butturini & Gale, 1988; De Witte et al, 1984; Glucksberg et al, 1974; Goldman et al, 1988; Plas et al, 1988; Schattenberg et al, 1990 ). Reduction of GVHD can be accomplished by T-cell depletion of the graft. However, the removal of immunocompetent T lymphocytes is associated with increased graft rejection and increased relapse rate Butturini & Gale, 1988; Goldman et al, 1988; Maraninchi et al, 1987; Marmont et al, 1991) . We have previously reported the outcome of 80 consecutive patients transplanted for acute and chronic leukaemia with HLA-identical sibling grafts depleted of lymphocytes by counterflow centrifugation. We concluded that the prob ability of survival and leukaemia-free survival (LFS) was comparable with the data of recipients of unmanipulated grafts (Schattenberg et al, 1990) . In the present analysis we extended our observations to 181 consecutive 750 © 1997 Blackwell Science Ltd
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transplanted for standard-risk acute and chronic leukaemia between 1981 and 1995. This is one of the largest groups of patients described in the literature transplanted with T-ceIIdepleted marrow grafts from a single centre. Median followup was 5-5 years (range 3 months to 14 years). The longer median follow-up and the higher number of patients enabled us to address the issues of sustained engraftment, acute and chronic GVHD, the impact of intensification of the con ditioning regimen by the addition of anthracyclines, the influence of the number of T lymphocytes infused within the graft, chimaerism, transplantation-related mortality, leukaemic relapse, long-term survival and LFS.
MATERIALS AND METHODS
Patients and donors. Between May 1981 and September 1995, 181 consecutive patients (105 males and 76 females) received a transplant for acute myeloid leukaemia in first complete remission (AML-CR1: n = 7 0), acute lymphoid leukaemia in first and second complete remission (ALL-CR1, CR2: n = 57) and chronic myeloid leukaemia in first chronic phase (CML-CP1: n = 54). Donors were HLA-identical and MLC-negative siblings. Median age of the recipients and the donors was 34 (range 1 3 -5 9 ) and 35 (range 1 1 -7 1 ) years, respectively. Informed consent was obtained from all recipients and donors or their guardians. Donor marrow was depleted of lymphocytes by density gradient centrifuga tion followed by counterflow centrifugation as previously described (De Witte et al, 1984; Plas et al, 1988) . The median number of T cells infused was 0-8 (range 0-1-3-2) x 10f7kg body weight. All patients were managed in single rooms with filtered air under positive pressure during their hospital stay. All patients received oral selective gut decontamination, as well as co-trimoxazole for Pneumocystis carinii prophylaxis and oral acyclovir for prophylaxis of herpes virus infections. The patient's characteristics are summarized in Table I .
Chemotherapy before allografting. All patients with CML had been treated with hydroxyurea or busulphan. In three patients interferon alpha was added. Patients with ALL and AML were in CR1 or CR2 after chemotherapy according to current EORTC (European Organization for Research and Treatment of Cancer) protocols.
Conditioning regimen. All patients were treated with cyclophosphamide (Cy) (60 mg/kg body weight) intra venously (i.v.) on days -6 and -5. Fractionated total body irradiation (TBI) was given to 174 patients in two equal fractions on days -2 and -1 to a total dose of either 9 Gy (n = 143) or 12 Gy (n = 31). Midline average dose rate was 4-1 ± 0 -5 cGy/min in 33 patients and 12-3 ± 2 -0 cGy/min in 141 patients. TBI was delivered by a 16 or 18 MV photon beam linear accelerator. Lungs and eyes were shielded to 7 or 8 Gy and 6 Gy, respectively, using individually adapted lead blocks. If the total dose was 12 Gy, the kidneys were shielded to 9 Gy. In an attempt to reduce relapse rate, the conditioning regimen was intensified in 116 patients by the addition of daunorubicine to a total dose of 15 6 mg/m2 body surface (n = 1 0 ) or demethoxy-daunorubicine (idarubicine) to a total dose of 42 mg/m2 body surface (n = 106) Raemaekers et al, 1989) . Anthracyclines were given by continuous i.v. infusion for 2 -7 d. However, the first cohort patients treated with anthracyclines showed significantly more severe oral mucositis and and delayed bone marrow recovery (Muus et al, 1993) . In the next cohort TBI was increased to 2 x 6 Gy and no anthracyclines were given. This resulted in a high 5-year probability of relapse of 57% (95% Cl 37-77% ). Since oral mucositis and delayed engraftment were schedule dependent, anthracyclines were reintroduced from February 1991 onwards and given on day -.11 and -12 instead of day -7 to -2 in combination with 2x4*5 Gy TBI. In seven recipients TBI was replaced by busulphan (4 mg/kg/d on each of 4 consecutive days). The donor marrow was infused 2 4 h after completion of TBI or 72 h after the last dose of busulphan.
Immunoprophylaxls after transplantation. Details of iminunoprophylaxis post-transplant have been described (Schattenberg et al, 1990 The differences between curves were tested for statistical significance with the two-tailed log-rank test. To determine whether diagnosis, recipient age, recipient sex, donor age, donor sex, chemotherapy before allografting, conditioning regimen, T-cell dose and GVHD prophylaxis were independent predictors of relapse, survival, leukaemiafree survival, acute GVHD, chronic GVHD and chimaerism, multivariate stepwise regresssion analysis was performed using Cox's proportional hazard regression. P values <0*05 were c Follow-up ended on 1 January 1996, Survival and relapse were followed to the time of last contact with the patient. Table I . Disease-, patient-, donor-, and treatment-related variables of 181 patients transplanted for acute and chronic leukaemia with and without the addition of anthracyclines in the conditioning regimen. Abbreviations: AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; CML, chronic myeloid leukaemia; CR1, first complete remission; CR2, second complete remission; CPI, first chronic phase; TBI, total body irradiation.
Conditioned with anthracyclines
Conditioned without anthracyclines
RESULTS
Engraftment
Six patients died within 22 d after BMT and were not evaluable for engraftment. Graft failure occurred in 4 /1 1 4 evaluable patients (3%) after conditioning with anthracyclines and in 4 /6 1 evaluable patients (7%) conditioned with the standard regimen. In both groups one patient never showed any sign of engraftment (primary graft failure). Another six patients rejected their graft (secondary graft failure) at 2 8 -1 7 2 d (median 106). 173 patients engrafted with leucocytes 5= l -0 x l 0 9/l at a median of 17d (range 1 0 -5 8 ) after BMT. The speed of engraftment did not differ between the patients who were conditioned with anthra cyclines at day -12 and -11 and the patients conditioned without anthracyclines. They engrafted at median 17 d (range 9 -3 5 ) and median 16 d (range 5 -5 8 ) after BMT, respectively. However, in patients conditioned with anthra cyclines from day -7 to day -2 engraftment was considerably delayed to a median of 20 d (range 8 -3 7 ).
Acute GVHD The characteristics of GVHD are summarized in Table II . 3 4 / 173 (20%) patients at risk developed acute GVHD ^ grade 2. GVHD grade 3 and 4 occurred in only 8 /1 7 3 patients (5%), and included the two patients who did not receive GVHD prophylaxis after BMT. The probability of acute GVHD 5= grade 2 at day 100 after BMT was 19% (95% confidence interval [Cl] 11-27% ). Using multivariate analysis acute GVHD > grade 2 was significantly higher in the patients conditioned with anthracyclines (Odds 2-56; P = 0-024). Patients transplanted for AML had more acute GVHD 5= grade 2 than ALL (Odds 2-27; P = 0*039) or CML (Odds 2 '63', P = 0*028) cases. We did not observe any significant relationship between T-cell dose in the marrow graft and acute GVHD.
after retransplantation and one patient died from sepsis 2 years after second BMT. 25 patients (AML: n = 9; CML: n = 11: ALL: n = 5) who relapsed from their original disease were treated with lymphocyte infusions from the original marrow donor (Bar el al, 1993 : Kolb et al, 1995 . 11 patients (44%) responded (AML: 72 = 1; ALL: 72 = 1; CML: n = 9) and reached a second haematological and cytogenetic remission. They are without any sign of relapse at the end of follow-up. Two patients with a relapse from CML who did not respond to lymphocyte infusions were retransplanted with unmani pulated donor marrow and both are alive without leukaemia at 33 and 23 months after retransplantation.
Chronic GVHD out of 152 patients (39%) with a follow-up of > 3 s developed chronic GVHD. The 5-year probability of extensive chronic GVHD was 11% (95% Cl 5-17% ).
in multivariate ant patients with a female donor developed less chronic GVHD than patients with a male donor (Odds 0 3 0 ; P = 0*0004). In contrast to acute GVHD, the risk for chronic GVHD increased with a relatively higher T-cell dose in the marrow graft (Odds 1*85; P = 0*039). No significant relationship was observed between intensification of the conditioning regimen by the addition of anthracylines and chronic GVHD, although the group treated with anthracyclines showed a trend to develop more chronic GVHD. Forty-eight patients (27%) relapsed after BMT. The projected 5-year probability of relapse was 39% (95% Cl 25-53% ) for AML-CR1, 32% (95% Cl 14-50% ) for ALL-CR1,2 and 39% (95% Cl .13-65%) for CML-CP1. The projected 5-year probability of relapse in all patients treated with anthra-2S was 26% (95% Cl 16-36% ). This was significantly lower than the probability of relapse of 52% (95% Cl 3 8 -66%) in all patients conditioned without the addition of anthracyclines (P = 0*015). These relapse curves are shown in Fig 1A. Probabilities of relapse for patients treated with and without anthracyclines are summarized in Table III . In multivariate analysis relapse rates were significantly lower in patients conditioned with the addition of anthracyclines (Odds 0*50: P = 0-044).
Two patients with relapse of CML were retransplanted after conditioning with 16 mg/kg busulphan alone without an attempt to induce CR with donor lymphocyte trans fusions. One patient died from subsequent relapse 17 months Survival One hundred and one of 181 patients (56%) were alive at 3 -166 months (median 63) after BMT, The projected 5-year probability of survival was 45% (95% Cl 32-58% ) for AML-CR1, 54% (95% Cl 42-66% ) for ALL-CR 1,2 and 70% (95% Cl 62-78% ) for CML-CP1. The projected 5-year probability of survival in all patients conditioned with anthracyclines was 62% (95% Cl 52-72%). This was significantly better than the 44% (95% Cl 33-55% ) obtained in all patients conditioned without anthracyclines (P = 0*01) (Fig IB) . Using multivariate analysis, survival was significantly better in those patients conditioned with anthracyclines compared to patients treated with cyclophosphamide and TBI only (Relative Risk 0*63, 95% Cl 0*41-0-99%; P = 0-044). Probabilities of survival for patients treated with and without anthracyclines are summarized in Table III .
Leukaemia-free survival
The projected 5-year probability of LFS after T-cell-depleted BMT was 44% (95% Cl 31-57% ) for AML-CR1, 53% (95% Cl 41-65% ) for ALL-CR 1,2 and 48% (95% Cl 34-62%) for CML-CP1. The projected 5-year probability of LFS in all patients conditioned with anthracyclines was 56% (95% Cl 46-66% ). This is significantly better than the 36% (95% Cl 25-47% ) probability of LFS obtained in all conditioned without anthracyclines (P = 0*004) (Fig 1C) . In multivariate analysis LFS was significantly better after conditioning with anthracyclines (Relative Risk 0-62, 95% Cl 0*41-0*94%; P = 0*02 5 ). Probabilities of LFS for patients treated with and without anthracyclines are given in Table  III . Increased survival and LFS can be explained by the significantly lower relapse in patients treated with anthra cyclines (probability of relapse: Odds ratio 0*50; P = 0*044). Projected at 5 years, probability of relapse, survival, and leukaemia-free survival for all patients conditioned with and without anthracyclines are summarized in Table III. ?tic chi mam Haemopoietic chimaerism was assessed at 6 and 12 months after BMT. Methods used were red blood cell phenotyping and cytogenetic analysis of bone marrow metaphases as described previously (Schattenberg et al 1989) . At 6 and 12 months after BMT, respectively, 131 and 100 patients were in complete remission. 19 patients had no discriminating marker at 6 months after BMT and 14 patients had no discriminating marker at 12 months after BMT. They were excluded from further analysis. If at one time point there was Chimaerism 5-year probability of relapse (% probability (95% coniidence interval)) Donor chimaera, 6 months after BMT 33 (2 0 -4 6 ) Mixed chimaera, 6 months after BMT 29 (1 6 -3 2 ) P = 0-376* Donor chimaera, 12 months after BMT 10 (0 -1 8 ) Mixed chimaera, 12 months after BMT 29 (1 4 -3 4 ) P = 0-004* * P value of differences in relapse rate in patients who were donor chimaera and mixed chimaera at 6 and 12 months after BMT. months after BMT (P = 0 3 76). However, patients who were mixed chimaera at 12 months after BMT were significantly more at risk to develop relapse of their original disease com pared to patients who were donor chimaera at 12 months after BMT (P = 0-004). In multivariate analysis the addition of anthracyclines to the conditioning regimen was the only significant factor contributing to a lower number of mixed chimaeras in patients at 6 months (Odds 0-54; P -0-027) and at 12 months (Odds 0-47; P = 0-032) after BMT.
Bone marrow transplantation with grafts of lymphocytes is associated with a higher incidence of graft failure. Graft failure occurred in 2-20% of HLA-identical T-cell-depleted sibling transplants compared to 0-2% of recipients of HLA-identical unmanipulated bone marrow (Champlin, 1993 lymphocytes are responsible for graft rejection, the low incidence of graft failure in our patients may be caused by the number and nature of lymphocytes given within the graft, the relatively high midline average TBI dose rate and the addition of anthracyclines to the conditioning regimen.
T-cell depletion is an effective prevention of GVHD as has been shown in experimental animal models and in man (Marmont et al, 1991; Prentice et al, 1984; van Bekkum, 1985) . In the present analysis the probability of acute GVHD grade 2 at day 100 after BMT compares favourably with the actuarial incidence of 40 identical unmanipulated from ) in recipients of HLAand is comparable with marrow Butturini & Gale, '1988; Goldman et al, 1988; Maraninchi et al, 1987; Marmont et al, 1991; Martelli & Aversa, 1993; Naparstek et al, 1995) . The incidence of acute GVHD ^ grade 2 was significantly higher in the patients conditioned with anthracyclines and in patients with AML-CR1 compared to patients with ALL-CR1, CR2 or CML-CP1. The addition of anthracyclines to the conditioning regimen may eliminate more immunocompe tent autologous T lymphocytes. As a consequence the balance may be tipped to the relatively low number of donor T lymphocytes given within the graft, leading to more GVHD and GVHD associated graft-versus-leukaemia effect.
In patients with AML-CR1 the higher cumulative dose of anthracyclines already used for remission and consolidation may have contributed to the increased probability of acute GVHD in this group of patients,
The 5-year probability of chronic GVHD and its extensive manifestation is in the same range of HLA-identical T-celldepleted transplants in other studies (Blaise et al, Filipovich et al, 1982; Maraninchi et al, 1987; Marmont et al, .1991; Martelli & Aversa, 1993; Mitsuyasu et al, 1986; Naparstek et al, 1995; Prentice et al, 1984) . In multivariate analysis we observed a relationship between the T-cell dose and the probability of developing chronic GVHD. Increasing the T-cell dose by only 1 '0 x 1 OfVkg body weight doubled the risk for chronic GVHD. Patients conditioned with anthra cyclines also developed more chronic GVHD, although this difference was not significant (P = ()•()56). In contrast to other studies we observed a significantly lower incidence of chronic GVHD if the donor was female. At present we cannot explain this observation other than that this may have occurred by chance. Although the addition of anthracyclines to the conditioning regimen is correlated with significantly more acute GVHD > grade 2 and associated with a trend towards more chronic GVHD, no higher transplant-related mortality was observed in this group of patients.
Prevention of leukaemic relapse is the ultimate goal in allogeneic BMT. In general, T-cell depletion significantly reduces LFS after BMT and this is caused by higher relapse rates. LFS after T-cell-depleted BMT for leukaemia in CR1 or CPI varied from 48% at 2 years to 25% at 7 years (Blaise et al, 1993; Marmont et al, 1991; Naparstek et al, 1995 Zittoun et al, 1995) . Recent cumulative clinical data from the International Bone Marrow Transplant Registry (IBMTR) showed a 2-year probability of relapse of 30% after transplantation with lymphocyte-depleted grafts for acute leukaemia in complete remission and 44% for chronic myeloid leukaemia in first chronic phase. These percentages were 17% and 10%, respectively, in recipients of HLA-identical unmanipu lated transplants (Marmont et al, 1991) . In the present study the intensification of the conditioning regimen with anthra cyclines in 116 patients increased 5-year LFS to between 51% and 62%. In the patients conditioned with the addition of anthracyclines, the 5-year probability of relapse was 26% and compared favourably with the 3 7% at 2 years from the IBMTR (Marmont et al, 1991) . In multivariate analysis, intensification of the conditioning regimen with anthra cyclines reduced the risk of relapse by 5 0% and was the only significant factor contributing to an increased probability of LFS. Using multivariate analysis, chemotherapy before allografting had no effect on the probability of engraftment, GVHD, mortality, relapse, survival and LFS after BMT. No other additional variables met the 0-05 significance level for entry in the statistical model. Anthracyclines, like other additional chemotherapeutics, may contribute to an increased eradication of the tumour burden especially in CML and result in lower relapse rates (Feler et al, 1982; Martelli & Aversa, 1993) . We have also shown that the addition of anthracyclines was correlated with increased probabilities of acute and chronic GVHD. This may have further enhanced the graft-versus-leukaemia effect.
Especially in patients with a relapse from CML after BMT, treatment with infusion of lymphocytes from the original marrow donor may induce second complete remission (Cullis et al, 1992; Drobyski et al, 1992; Kolb et al, 1990 Kolb et al, , 1995 . 11 patients who relapsed from CML-CP1 were treated with lymphocyte infusions from the donor and nine patients (82%) responded. If we correct our data for patients in first and second remission, the 5-year probability of LFS from Tcell-depleted BMT onward would increase from 48% (95% Cl 34-62% ) to 67% (95% Cl 58-76% ).
Using red blood cell phenotyping and cytogenetic analysis of the bone marrow, evaluation of chimaerism at 6 months and 1 year after BMT showed high incidences of mixed chimaerism. T are comparable with chimaerism studies after transplantation with T-cell-depleted marrow grafts (Bertheas et al, Roy et al, 1990; Schattenberg et al, 1989) . In a previous analysis we showed that mixed chimaerism at 6 months after BMT was not correlated with higher incidence of relapse (Schattenberg et al, 1990 . The data in this study confirm this conclusion. However, if we evaluate the chimaerism status at 12 months after BMT, mixed chimaerism is correlated with an increased probability of relapse. The differences in relapse rate may be explained by a relatively high number of patients who were still mixed chimaera at 6 months after BMT and changed to complete donor chimaera at 12 months after BMT. Another explanation may be selection of patients transplanted for CML. Patients transplanted for AML and ALL usually relapse early after BMT and progression to relapse is usually very rapid, resulting in a relatively higher number of observed donor chimaeras that relapse. Data in the literature concerning the influence of mixed chimaerism at one time point post-BMT on the risk of leukaemic relapse (McCann & Lawler, 1993) . Investigating chimaerism using serial analysis over time is essential in order to validate the significance of mixed chimaerism after BMT and is being assessed in an ongoing { In the present analysis we show that BMT with grafts deleted of lymphocyes by counterflow c in low graft failure. Intensification of the c the addition of anthracyclines decreased relapse rate increas are probability of LFS. rJ data favourably with other studies using T-cell depletion (Blaise et al, 1993; Bordignon et al, 1989; Champlin, 1993 Patterson et al, 1986 ). The probability of survival and LFS is equivalent to that reported in the literature for recipients of untreated grafts, but the morbidity due to GVHD is low. In patients transplanted for CML, relapse can be treated with donor lymphocytes. This may be very important for the future of T-cell-depleted BMT. In patients with AML and ALL further efforts should be made to reduce relapse rate. Adoptive immunotherapy by delayed or selected lymphocyte add-back after T-cell-depleted BMT in patients with a high probability of relapse is one of the possibilities currently under investigation.
